Greenville-based Zylo Therapeutics creates spinoff company
Greenville-based Zylö Therapeutics has created a spinoff company to market its trademarked Z-pod topical delivery platform in the pharmaceutical industry.Atticus Pharma Inc. is initially focused on the joint development agreement with Yuva Biosciences, where Atticus has the worldwide, exclusive rights to YuvaBio’s Y20, a terminalia chebula extract for the treatment of alopecia-related conditions and for wound-healing, according to a news release. The Z-pod delivery technology, licensed from Albert Einstein College of Medicine, is based on silica-derived particles — called Z-pods, the release stated. Zylö can embed an active ingredient of choice into these particles, thereby providing sustained delivery that nourishes/treats the skin for 24-plus hours. Read more >>